New concepts of biobanks-strategic chance for uro-oncology

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 4, 2010, Pages 449-457

  Goebell, Peter J ^a   Morente, Manuel M ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Structural Biology and Biocomputing Programme   (Spain)

Author keywords

Biobanking; Biorepositories; Bladder cancer; Uro oncology

Indexed keywords

BIOBANK; CANCER RESEARCH; GENETIC SUSCEPTIBILITY; HEALTH CARE FACILITY; HEALTH CARE POLICY; LIFESTYLE; MOLECULAR BIOLOGY; ONCOLOGY; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; URINARY TRACT CANCER; HUMAN; ORGANIZATION AND MANAGEMENT; STANDARDS;

HUMANS; TISSUE BANKS; UROLOGIC NEOPLASMS;

EID: 77953846282     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.03.012     Document Type: Review

References (97)

1. Steinberg K., Beck J., Nickerson D., et al. DNA banking for epidemiologic studies: A review of current practices. Epidemiology 13 (2002) 246-254
2. Chadwick R. The Icelandic database-do modern times need modern sagas?. BMJ 319 (1999) 441-444
3. Palmer L.J. UK Biobank: Bank on it. Lancet 369 (2007) 1980-1982
4. Boomsma D.I., de Geus E.J., Vink J.M., et al. Netherlands Twin Register: From twins to twin families. Twin Res Hum Genet 9 (2006) 849-857
5. Lichtenstein P., De Faire U., Floderus B., et al. The Swedish Twin Registry: A unique resource for clinical, epidemiological, and genetic studies. J Intern Med 252 (2002) 184-205
6. http://epic.iarc.fr (last accessed March 2010)
7. Puente D., Malats N., Cecchini L., et al. Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. Eur Urol 43 (2003) 53-62
8. Nieuwenhuijsen M.J., Smith R., Golfinopoulos S., et al. Health impacts of long-term exposure to disinfection byproducts in drinking water in Europe: HiWATE. J Water Health 7 (2009) 185-207
9. http://www.hcanc.org.br/en/index.php?page=477 (last accessed March 2010)
10. http://www.eurocord.org (last accessed March 2010)
11. http://www.tubafrost.org/ (last accessed March 2010)
12. http://biospecimens.cancer.gov (last accessed March 2010)
13. http://www.ctg.queensu.ca/TissueBank/ (last accessed March 2010)
14. https://www.ctrnet.ca/ (last accessed March 2010)
15. Morente M.M., de Alava E., and Fernandez P.L. Tumor banking: The Spanish design. Pathobiology 74 (2007) 245-250
16. http://www.walescancerbank.com/index.html (last accessed March 2010)
17. http://www.biobankireland.com (last accessed March 2010)
18. http://www.stn.org.sg/ (last accessed March 2010)
19. Ozols R.F., Herbst R.S., Colson Y.L., et al. Clinical cancer advances 2006: Major research advances in cancer treatment, prevention, and screening: A report from the American Society of Clinical Oncology. J Clin Oncol 25 (2007) 146-162
20. Morente M.M., Fernandez P.L., and de Alava E. Biobanking: Old activity or young discipline?. Semin Diagn Pathol 25 (2008) 317-322
21. Cambon-Thomsen A., Rial-Sebbag E., and Knoppers B.M. Trends in ethical and legal frameworks for the use of human biobanks. Eur Respir J 30 (2007) 373-382
22. Riegman P.H., Dinjens W.N., and Oosterhuis J.W. Biobanking for interdisciplinary clinical research. Pathobiology 74 (2007) 239-244
23. OECD. Biological Resource Centers: Underpinning the Future of Life Sciences and Biotechnology (2001), OECD, Paris. http://www.oecd.org/dataoecd/55/48/2487422.pdf (last accessed March 2010)
24. Malkin A. Tumor markers. In: Tannock I.F., and Hill R.P. (Eds). The basic science of oncology. 2nd ed. (1992), McGraw-Hill, New York 196-206
25. Gudjónsson S., Isfoss B.L., Hansson K., et al. The value of the UroVysion Assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 54 (2008) 402-408
26. Birkhahn M., Mitra A.P., and Cote R.J. Molecular markers for bladder cancer: The road to a multimarker approach. Expert Rev Anticancer Ther 7 (2007) 1717-1727
27. Herrmann E., Eltze E., Bierer S., et al. VEGF-C, VEGF-D, and Flt-4 in transitional bladder cancer: Relationships to clinicopathologic parameters and long-term survival. Anticancer Res 27 (2007) 3127-3133
28. Tsai Y.S., Tzai T.S., and Chow N.H. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?. Urol Int 79 (2007) 210-216
29. Knowles M.A. Role of FGFR3 in urothelial cell carcinoma: Biomarker and potential therapeutic target. World J Urol 25 (2007) 581-593
30. Mohammed A., Khan Z., Zamora I., et al. Biological markers in the diagnosis of recurrent bladder cancer: An overview. Expert Rev Mol Diagn 8 (2008) 63-72
31. Droller M.J. Cancer heterogeneity and its biological implications in the grading of urothelial carcinoma. J Urol 165 (2001) 696-697
32. Kyzas P.A., Denaxa-Kyza D., and Ioannidis J.P. Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 43 (2007) 2559-2579
33. Kyzas P.A., Denaxa-Kyza D., and Ioannidis J.P. Quality of reporting of cancer prognostic marker studies: Association with reported prognostic effect. J Natl Cancer Inst 99 (2007) 236-243
34. McShane L.M., Altman D.G., Sauerbrei W., et al., Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 100 (2006) 229-235
35. Altman D.G., Lausen B., Sauerbrei W., et al. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86 (1994) 829-835
36. Schmoor C., Sauerbrei W., and Schumacher M. Sample size considerations for the evaluation of prognostic factors in survival analysis. Stat Med 19 (2000) 441-452
37. Pajak T.F., Clark G.M., Sargent D.J., et al. Statistical issues in tumor marker studies. Arch Pathol Lab Med 124 (2000) 1011-1015
38. Altman D.G., and Royston P. What do we mean by validating a prognostic model?. Stat Med 19 (2000) 453-473
39. Begg C.B., Cramer L.D., Venkatraman E.S., et al. Comparing tumor staging and grading systems: A case study and a review of the issues, using thymoma as a model. Stat Med 19 (2000) 1997-2014
40. Simon R., and Altman D.G. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69 (1994) 979-985
41. McGuire W.L. Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83 (1991) 154-155
42. Stockler M.R., Boyd N.F., and Tannock I.F. Guide to studies of diagnostic tests, prognostic factors, and treatments. In: Tannock I.F., and Hill R.P. (Eds). The basic science of oncology. 3rd ed. (1998), McGraw-Hill, New York 466-492
43. Drew P.J., Ilstrup D.M., Kerin M.J., et al. Prognostic factors: Guidelines for investigation design and state of the art analytical methods. Surg Oncol 7 (1998) 71-76
44. Grossman H.B. The first and second International Workshops on diagnostic and prognostic markers in bladder cancer. Urol Oncol 5 (2000) 183-184
45. Goebell P.J., Groshen S., Schmitz-Dräger B.J., et al. The International Bladder Cancer Bank: Proposal for a new study concept. Urol Oncol 22 (2004) 277-284
46. Goebell P.J., Groshen S.L., and Schmitz-Dräger B.J. Guidelines for development of diagnostic markers in bladder cancer. World J Urol 26 (2008) 5-11
47. Goebell P.J., Groshen S., Schmitz-Dräger B.J., et al. Concepts for banking tissue in urologic oncology: The International Bladder Cancer Bank. Clin Cancer Res 11 (2005) 413-415
48. Stephan C., Kohl M., Turewicz M., et al. Using Laboratory Information Management Systems as central part of a proteomics data workflow. Proteomics 10 (2010) 1230-1249
49. Helsens K., Colaert N., Barsnes H., et al. MS_lims, a simple yet powerful open source laboratory information management system for MS-driven proteomics. Proteomics 10 (2010) 1261-1264
50. Stocker G., Fischer M., Rieder D., et al. iLAP: A workflow-driven software for experimental protocol development, data acquisition, and analysis. BMC Bioinformatics 10 (2009) 390
51. Wang N., Sherwood A.R., Kurihara A., et al. The Hawaiian Algal Database: A laboratory LIMS and online resource for biodiversity data. BMC Plant Biol 9 (2009) 117
52. Ulma W., and Schlabach D.M. Technical considerations in remote LIMS access via the World Wide Web. J Autom Methods Manag Chem 2005 (2005) 217-222
53. Betsou F., Barnes R., Burke T., et al. Human biospecimen research: Experimental protocol and quality control tools. Cancer Epidemiol Biomarkers Prev 18 (2009) 1017-1025
54. Riegman P.H., Morente M.M., Betsou F., et al., Marble Arch International Working Group on Biobanking for Biomedical Research. Biobanking for better healthcare. Mol Oncol 2 (2008) 213-222
55. Elliott P., Peakman T.C., and UK Biobank. The UK Biobank sample handling and storage protocol for the collection, processing, and archiving of human blood and urine. Int J Epidemiol 37 (2008) 234-244
56. International Society for Biological and Environmental Repositories (ISBER). Best practices for repositories: Collection, storage, retrieval, and distribution of biological materials for research. Cell Preserv Technol 6 (2008) 3-58. http://www.isber.org/Pubs/BestPractices2008.pdf (last accessed March 2010)
57. Landi M.T., and Caporaso N. Sample collection, processing, and storage. IARC Sci Publ 142 (1997) 223-236
58. Wallace H. The need for independent scientific peer review of Biobank UK. Lancet 359 (2002) 2282
59. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
60. Patel A.A., Gilbertson J.R., Parwani A.V., et al., Cooperative Prostate Cancer Tissue Resource. An informatics model for tissue banks-lessons learned from the Cooperative Prostate Cancer Tissue Resource. BMC Cancer 6 (2006) 120
61. Andriole G.L., Reding D., Hayes R.B., et al., PLCO Steering Committee. The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise. Urol Oncol 22 (2004) 358-361
62. Zhu C., Pinsky P., Carrick D., et al. PLCO Biospecimens as an Unbiased Resource for Cancer Biomarker Research Presentation (March, 2009) Proceedings of the 2nd Annual Biospecimen Research Network (BRN) Symposium. Advancing Cancer Research through Biospecimen Science. Bethesda, (MD)
63. van Gils M.P., Stenman U.H., and Schalken J.A. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol 48 (2005) 1031-1041
64. http://www.doh.gov.uk/cancer/prostate.htm (last accessed March 2010)
65. Wullich B., Wernet N., and Unteregger G. 6th International Workshop of the German Prostate Cancer Consortium (DPKK e.V.). Urologe A 48 (2009) 299-301
66. Retz M., Hartmann A., Merseburger A., et al. The German Association for Bladder Cancer Research. Urologe A 47 (2008) 1141-1142
67. http://www.mdanderson.org/departments/bladderSPORE (last accessed March 2010)
68. Vlahou A., Schanstra J., Frokiaer J., et al. Establishment of a European Network for Urine and Kidney Proteomics. J Proteom 71 (2008) 490-492
69. NCI Best Practices for Specimen Resources (2007). http://biospecimens.cancer.gov/global/pdfs/NCI_Best_Practices_060507.pdf NCI, Bethesda, NCI. (last accessed March 2010)
70. OECD Best Practice Guidelines for Biological Resource Centers - General Best Practice Guidelines for all BRCs (2007), OECD, Paris. http://www.oecd.org/dataoecd/7/13/38777417.pdf (last accessed March 2010)
71. World Cancer Report 2008 (2008), IARC/WHO, Lyon. http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.php (last accessed March 2010)
72. Common minimum technical standards and protocols for biological resource centers dedicated to cancer research, WorkGroup Report 2 (2007), IARC/WHO, Lyon. http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk2/index.php (last accessed March 2010)
73. Morente M.M., Mager R., Alonso S., et al. TuBaFrost 2: Standardizing tissue collection and quality control procedures for a European virtual frozen tissue bank network. Eur J Cancer 42 (2006) 2684-2691
74. Riegman P.H., Bosch A.L., and OECI TuBaFrost Consortium. OECI TuBaFrost tumor biobanking. Tumori 94 (2008) 160-163
75. Huang J., Qi R., Quackenbush J., et al. Effects of ischemia on gene expression. J Surg Res 99 (2001) 222-227
76. Dash A., Maine I.P., Varambally S., et al. Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. Am J Pathol 161 (2002) 1743-1748
77. Almeida A., Thiery J.P., Magdele′nat H., et al. Gene expression analysis by real-time reverse transcription polymerase chain reaction: Influence of tissue handling. Anal Biochem 328 (2004) 101-108
78. Blackhall F.H., Pintilie M., Wigle D.A., et al. Stability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resection. Neoplasia 6 (2004) 761-767
79. Spruessel A., Steimann G., Jung M., et al. Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. Biotechniques 36 (2004) 1030-1037
80. Micke P., Ohshima M., Tahmasebpoor S., et al. Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens. Lab Invest 86 (2006) 202-211
81. Downey P., and Peakman T.C. Design and implementation of a high-throughput biological sample processing facility using modern manufacturing principles. Int J Epidemiol 37 (2008) i46-i50
82. McQuillan A.C., and Sales S.D. Designing an automated blood fractionation system. Int J Epidemiol 37 (2008) i51-i55
83. Owen J.M., and Woods P. Designing and implementing a large-scale automated -80°C archive. Int J Epidemiol 37 (2008) i56-i61
84. Fagan M., and Ball P. Design and implementation of a large-scale liquid nitrogen archive. Int J Epidemiol 37 (2008) i62-i64
85. Grizzle W.E., Aamodt R., Clausen K., et al. Providing human tissues for research: How to establish a program. Arch Pathol Lab Med 122 (1998) 1065-1076
86. Peakman T.C., and Elliott P. The UK Biobank sample handling and storage validation studies. Int J Epidemiol 37 (2008) i2-i6
87. Elliott P., Peakman T.C., and UK Biobank. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol 37 (2008) 234-244
88. Mager S.R., Oomen M.H., Morente M.M., et al. Standard operating procedure for the collection of fresh frozen tissue samples. Eur J Cancer 43 (2007) 828-834
89. Troyer D. Biorepository standards and protocols for collecting, processing, and storing human tissues. Methods Mol Biol 441 (2008) 193-220
90. Chaigneau C., Cabioch T., Beaumont K., et al. Serum biobank certification and the establishment of quality controls for biological fluids: Examples of serum biomarker stability after temperature variation. Clin Chem Lab Med 45 (2007) 1390-1395
91. Langellé J., Panopoulos E., and Betsou F. Soluble CD40-ligand as a biomarker for storage-related preanalytic variations of human serum cytokine. Cytokine 44 (2008) 275-282
92. Betsou F., Luzergues A., Carter A., et al. Towards norms for accreditation of biobanks for human health and medical research: Compilation of existing guidelines into an ISO certification/accreditation normcompatible format. Qual Assur J 11 (2008) 221-294
93. http://www.marblearchgroup.org/index.php (last accessed March 2010)
94. http://www.isber.org/ (last accessed March 2010)
95. http://www.p3gconsortium.org/ (last accessed March 2010)
96. Oosterhuis J.W., Coebergh J.W., and van Veen E.B. Tumor banks: Well-guarded treasures in the interest of patients. Nat Rev Cancer 3 (2003) 73-77
97. Ringborg U., de Valeriola D., van Harten W., et al. Improvement of European translational cancer research. Collaboration between comprehensive cancer centers. Tumori 94 (2008) 143-146